Display options
Cite
Prasanna Kumar KM, Mohan V, Sethi B, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Indian J Endocrinol Metab. 2016;20(3):372-80doi: 10.4103/2230-8210.179996.
Prasanna Kumar, K. M., Mohan, V., Sethi, B., Gandhi, P., Bantwal, G., Xie, J., Meininger, G., & Qiu, R. (2016). Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Indian journal of endocrinology and metabolism, 20(3), 372-80. https://doi.org/10.4103/2230-8210.179996
Prasanna Kumar, K M, et al. "Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India." Indian journal of endocrinology and metabolism vol. 20,3 (2016): 372-80. doi: https://doi.org/10.4103/2230-8210.179996
Prasanna Kumar KM, Mohan V, Sethi B, Gandhi P, Bantwal G, Xie J, Meininger G, Qiu R. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Indian J Endocrinol Metab. 2016 May-Jun;20(3):372-80. doi: 10.4103/2230-8210.179996. PMID: 27186557; PMCID: PMC4855968.
Copy Download .nbib Format: NLM
Share it on

Indian J Endocrinol Metab. 2016 May-Jun;20(3):372-80. doi: 10.4103/2230-8210.179996.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.

Indian journal of endocrinology and metabolism

K M Prasanna Kumar, Viswanathan Mohan, Bipin Sethi, Pramod Gandhi, Ganapathi Bantwal, John Xie, Gary Meininger, Rong Qiu

Affiliations

  1. Bangalore Diabetes Hospital, Bengaluru, Karnataka, India.
  2. Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.
  3. CARE Hospitals, Hyderabad, Telangana, India.
  4. Gandhi Research Institute, Nagpur, Maharashtra, India.
  5. Department of Endocrinology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India.
  6. Janssen Research and Development, LLC, Raritan, NJ, USA.

PMID: 27186557 PMCID: PMC4855968 DOI: 10.4103/2230-8210.179996

Abstract

BACKGROUND: This post hoc analysis evaluated the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) from India.

METHODS: Changes from baseline in HbA1c, fasting plasma glucose (FPG), body weight, and blood pressure (BP) with canagliflozin 100 and 300 mg were evaluated in a subgroup of patients from India (n = 124) from 4 randomized, double-blind, placebo- and active-controlled, Phase 3 studies (N = 2313; Population 1). Safety was assessed based on adverse event (AE) reports in these patients and in a broader subgroup of patients from India (n = 1038) from 8 randomized, double-blind, placebo- and active-controlled, Phase 3 studies (N = 9439; Population 2).

RESULTS: Reductions in HbA1c with canagliflozin 100 and 300 mg were -0.74% and -0.88%, respectively, in patients from India, and -0.81% and -1.00%, respectively, in the 4 pooled Phase 3 studies. In the Indian subgroup, both canagliflozin doses provided reductions in FPG, body weight, and BP that were consistent with findings in the overall population. The incidence of overall AEs in patients from India was generally similar with canagliflozin 100 and 300 mg and noncanagliflozin. The AE profile in patients from India was generally similar to the overall population, with higher rates of genital mycotic infections and osmotic diuresis-related and volume depletion-related AEs with canagliflozin versus noncanagliflozin.

CONCLUSION: Canagliflozin provided glycemic control, body weight reduction, and was generally well tolerated in patients with T2DM from India.

Keywords: Fasting blood glucose; HbA1c; hyperglycemia; oral medications; type 2 diabetes

References

  1. Cardiovasc Diabetol. 2014 Mar 28;13:65 - PubMed
  2. Am Heart J. 2013 Aug;166(2):217-223.e11 - PubMed
  3. Diabetologia. 2011 Dec;54(12):3022-7 - PubMed
  4. Diabetes Obes Metab. 2013 May;15(5):432-40 - PubMed
  5. Diabetes Obes Metab. 2012 Jun;14(6):539-45 - PubMed
  6. Diabetologia. 2013 Dec;56(12):2582-92 - PubMed
  7. Hosp Pract (1995). 2013 Apr;41(2):72-84 - PubMed
  8. Diabetes Obes Metab. 2013 Dec;15(12):1136-45 - PubMed
  9. J Fam Pract. 2010 Sep;59(9 Suppl 1):S5-9 - PubMed
  10. J Diabetes Investig. 2015 Mar;6(2):210-8 - PubMed
  11. Diabetes Obes Metab. 2014 May;16(5):467-77 - PubMed
  12. Diabetes. 2014 Jan;63(1):53-5 - PubMed
  13. Diabetes Obes Metab. 2013 May;15(5):463-73 - PubMed
  14. PLoS One. 2014 Aug 28;9(8):e105638 - PubMed
  15. Diabetes Metab Res Rev. 2012 Mar;28(3):268-75 - PubMed
  16. Diabetologia. 2014 May;57(5):891-901 - PubMed
  17. Diabetes Obes Metab. 2013 Apr;15(4):372-82 - PubMed
  18. Diabetes Res Clin Pract. 2009 Jan;83(1):106-16 - PubMed
  19. J Diabetes. 2012 Sep;4(3):227-37 - PubMed
  20. Lancet. 2013 Sep 14;382(9896):941-50 - PubMed
  21. Diabetes Care. 2013 Sep;36(9):2508-15 - PubMed
  22. Indian J Med Res. 2007 Mar;125(3):217-30 - PubMed
  23. Diabetes Obes Metab. 2015 Jan;17(1):23-31 - PubMed
  24. J Clin Endocrinol Metab. 2013 May;98(5):E867-71 - PubMed
  25. Diabetes Res Clin Pract. 2011 Nov;94(2):217-24 - PubMed
  26. Diabetes Res Clin Pract. 2014 Feb;103(2):137-49 - PubMed
  27. Int J Behav Med. 2012 Jun;19(2):121-33 - PubMed
  28. Diabetes Care. 2012 Jun;35(6):1232-8 - PubMed
  29. Int J Clin Pract. 2013 Dec;67(12):1267-82 - PubMed
  30. Clin Ther. 2014 Jan 1;36(1):84-100.e9 - PubMed
  31. Diabetes Obes Metab. 2014 Oct;16(10):1016-27 - PubMed
  32. Diabetes Care. 2015 Mar;38(3):355-64 - PubMed
  33. Diabetes Obes Metab. 2012 Aug;14(8):737-44 - PubMed
  34. Curr Med Res Opin. 2014 Feb;30(2):163-75 - PubMed
  35. Indian J Endocrinol Metab. 2014 May;18(3):355-60 - PubMed
  36. Expert Opin Pharmacother. 2014 Aug;15(11):1501-15 - PubMed
  37. J Clin Pharmacol. 2013 Jun;53(6):601-10 - PubMed
  38. Ann N Y Acad Sci. 2013 Apr;1281:64-91 - PubMed
  39. Diabetes Obes Metab. 2015 Mar;17(3):294-303 - PubMed

Publication Types